phenol has been researched along with Multiple Sclerosis in 3 studies
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We previously reported that relapsing remitting multiple sclerosis patients treated with dimethyl fumarate have a prominent depletion of the gut microbiota, thereby suggesting that studying the composition of plasma and CSF samples from these patients may help to identify microbially derived metabolites." | 4.12 | Bacterial neurotoxic metabolites in multiple sclerosis cerebrospinal fluid and plasma. ( Amatruda, M; Button, J; Casaccia, P; Edwards, K; Frazier, C; Inbar, B; Kiebish, MA; Kim-Schulze, S; Lublin, F; Ntranos, A; Park, HJ; Tolstikov, V; Wentling, M, 2022) |
| "Treatment of spasticity poses a major challenge given the complex clinical presentation and variable efficacy and safety profiles of available drugs." | 2.53 | Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. ( Comi, G; Gold, R; Hartung, HP; Montalban, X; Otero-Romero, S; Sastre-Garriga, J; Soelberg Sørensen, P; Thompson, AJ; Vermersch, P, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ntranos, A | 1 |
| Park, HJ | 1 |
| Wentling, M | 1 |
| Tolstikov, V | 1 |
| Amatruda, M | 1 |
| Inbar, B | 1 |
| Kim-Schulze, S | 1 |
| Frazier, C | 1 |
| Button, J | 1 |
| Kiebish, MA | 1 |
| Lublin, F | 1 |
| Edwards, K | 1 |
| Casaccia, P | 1 |
| Otero-Romero, S | 1 |
| Sastre-Garriga, J | 1 |
| Comi, G | 1 |
| Hartung, HP | 1 |
| Soelberg Sørensen, P | 1 |
| Thompson, AJ | 1 |
| Vermersch, P | 1 |
| Gold, R | 1 |
| Montalban, X | 1 |
| Ewing, R | 1 |
| Choa, B | 1 |
| Shuttleworth, KE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of EXOPULSE Mollii Suit on Spasticity and Muscular Oxygenation in Patients With Multiple Sclerosis.[NCT05912595] | 36 participants (Anticipated) | Interventional | 2023-05-18 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for phenol and Multiple Sclerosis
| Article | Year |
|---|---|
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
Topics: Amines; Analgesics; Baclofen; Cannabidiol; Clonidine; Cyclohexanecarboxylic Acids; Dantrolene; Diaze | 2016 |
2 other studies available for phenol and Multiple Sclerosis
| Article | Year |
|---|---|
Bacterial neurotoxic metabolites in multiple sclerosis cerebrospinal fluid and plasma.
Topics: Animals; Biomarkers; Dimethyl Fumarate; Humans; Indican; Multiple Sclerosis; Multiple Sclerosis, Rel | 2022 |
Pelvic evoked responses.
Topics: Adult; Aged; Anal Canal; Electromyography; Evoked Potentials; Female; Humans; Middle Aged; Multiple | 1983 |